On Tuesday, two promoter entities of Alkem Laboratories, Jayanti Sinha and the Samprada & Nanhamati Singh Family Trust, sold a combined 1.5% stake in the company for approximately ₹930 crore through open market transactions. This sale involved 17,88,220 shares, representing a 1.49% stake, which were offloaded at an average price of ₹5,200 per share, leading to a total transaction value of ₹929.87 crore. Following this transaction, Jayanti Sinha exited the company, resulting in a reduction of the promoter holding from 51.20% to 49.71%. The shares were purchased by various prominent investors, including ICICI Prudential Mutual Fund, HDFC Mutual Fund, and Goldman Sachs. In response to this news, Alkem Laboratories' stock price declined by 1.42%, closing at ₹5,239 on the National Stock Exchange (NSE). This divestment reflects a significant shift in the ownership structure of the pharmaceutical firm, raising interest among market analysts regarding its future performance and investor sentiment.